SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- Anixa Biosciences,
Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing
the body's immune system in the fight against cancer, today
announced that data related to Anixa's recently launched Cchek™
Prostate Cancer Confirmation test (Cchek™ PCC) will be presented at
the "AI and Big Data in Cancer: From Innovation to Impact"
conference. Cchek™ is Anixa's artificial intelligence (AI)
driven cancer detection technology.
The "AI and Big Data in Cancer" conference takes place
March 29-31, 2020 at the Westin
Boston Waterfront in Boston,
Massachusetts and is designed to accelerate the
implementation of AI in oncology care. The conference will
showcase the impact the technology has had on diagnosis, treatment
decisions and patient care and illustrate how technology, data and
analytics innovations can be translated into clinical
practices. The meeting will be attended by researchers,
academics, clinicians, technologists, entrepreneurs, regulators and
insurance payers.
Details of the presentation are as follows:
Abstract title: Using artificial intelligence to
detect prostate cancer – how a flow cytometry-based liquid biopsy
assay can help reduce the number of unnecessary prostate biopsies
performed each year
Authors: George
Dominguez, PhD, John Roop,
Anthony Campisi, Amit Kumar, PhD
Presenting Author: George
Dominguez, PhD
Poster Number: P.14
Room: Grand Ballroom C,D,E
Presentation Dates and Times: Sunday, March 29, 2020 (6:00 PM – 7:00
PM)
Monday,
March 30, 2020 (1:00 PM –
2:00 PM)
Tuesday,
March 31, 2020 (1:00 PM –
2:00 PM)
About Cchek™
Cchek™ is an early cancer detection
technology, that measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method that offers improved
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
In December 2019, Anixa announced the
commercial launch of the Cchek™ Prostate Cancer Confirmation
test (Cchek™ PCC), the first test developed with the
Cchek™ liquid biopsy technology.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-at-ai-and-big-data-in-cancer-conference-301013718.html
SOURCE Anixa Biosciences, Inc.